At present, intravitreal administration of various anti-VEGF agents is the most important treatment in ARMD treatment, and it has been widely demonstrated that vision loss due to w-ARMD could be markedly prevented by this intervention (7). This evidence concerns the gene VEGFA and age-related macular degeneration.